鳜小肽转运载体PepT1基因分子特征及其表达研究

小肽转运载体（PepT1）是低亲和力、高容量的肽转运载体,在小肽的吸收过程中发挥着重要的作用。研究采用同源克隆和RACE技术克隆了鳜鱼（Siniperca chuatsi） PepT1基因全长cDNA序列,其cDNA序列全长为2480 bp,包含43 bp的5'UTR序列,232 bp的3'UTR序列,以及2205 bp开放阅读框,编码735个氨基酸。 氨基酸序列同源性分析结果显示,鳜鱼与石斑鱼（Epinephelus aeneus）、鲈鱼（Dicentrarchus labrax）PepT1间同源性均为89%,与其他非鱼类物种的同源性则在46%56%。经预测,鳜鱼PepT1编码蛋白的分子量为64.8 kD,等电点为8.97,该蛋白具有与哺乳动物同源蛋白相似的12 个螺旋跨膜结构,并且在跨膜区9和10之间有一个大的外环;跨膜区氨基酸高度保守,并存在有5个膜外N-糖基化位点和3个膜内含蛋白激酶C基序的相同区域。实时荧光定量表达分析表明,鳜鱼PepT1基因在前肠和中肠中表达量显著高于后肠（P0.05）,这说明前、中肠是鳜鱼肠道吸收小肽的主要部位;在胚后不同发育阶段鳜鱼前肠均能检测到PepT1基因的表达,并且在10 g个体中表达量最高,之后随着体重的增加其表达量维持在一个稳定水平。本研究结果首次报道了鳜鱼PepT1基因全序列及其分子表达特征,为鱼类营养及生理学的研究提供有价值的参考资料。       

穿膜肽介导的新型基因转运载体的功能研究

目的：借助穿膜肽TAT高效跨膜的特性和LacI前头肽突变体（LacI HPM）高亲和力结合DNA的特性,建立-种安全高效、无基因插入片段大小限制的基因转导系统。方法：在TAT-LacI HPM片段C端和N端分别添加GST标签,构建pET-28a（＋）-TAT-LacI HPM-GST和pGEX-GST-TAT-LacI HPM重组表达载体,可溶性表达TAT-LacI HPM-GST及GST-TAT-LacI HPM融合蛋白并纯化,获得TAT-LacI HPM二聚体,免疫荧光检测TAT-LacI HPM融合蛋白穿过HeLa细胞膜的情况,观察EGFP的表达,用免疫印迹检测TAT-LacI HPM融合蛋白介导质粒DNA进入细胞的能力。结果：表达、纯化并获得二聚体融合蛋白,体内实验表明其具有跨膜能力,能介导带有LacI结合序列的DNA质粒进入细胞,并在转染细胞里检测到了目的蛋白。结论：初步证实TAT-LacI HPM融合蛋白作为-种新型通用性非病毒DNA转运载体的可行性,为评价这种新型DNA疫苗载体在提高免疫效果方面的可行性奠定了前期实验基础。     

穿膜肽的结构特点和穿膜机制

穿膜肽（penetratin）是果蝇的触角足同源异形域的DNA结合结构域第三个片段的商品名,由16个氨基酸残基组成,它可以介导多种疏水大分子进入活体细胞质内而不破坏细胞膜的完整性;其最大的特点是可以介导多种大分子进入细胞内,并且无需外源能量,分子作为整体插入细胞内,穿膜过程不需解折叠。该发现开辟了药物进入细胞的新的介导途径。该文介绍穿膜肽的结构特点、穿膜机制、应用及局限性。     

膜穿透肽介导的核酸转运

以能通透生物膜的膜穿透肽为载体,使其携带DNA或寡核苷酸进入细胞,这种新型的核酸转运方法不仅体内外均有效,而且毒性很低。预计该方法在未来的生物工程和基因治疗中将发挥重要作用。     

细胞穿膜肽作为药物载体的研究进展

由于细胞膜的天然屏障作用,大多数具有治疗作用的极性分子、多肽、寡聚核苷酸很难进入细胞内发挥药效作用[1~3],因此很多具有良好治疗功能的大分子生物活性物质在实际应用中受到了极大的限制.为了克服这一治疗障碍和药物的转运,人们已经发展了各种穿透细胞膜的技术[4].目前通过细胞膜向细胞内转运的技术有病毒载体和非病毒载体.非病毒载体包括电穿孔、显微注射和脂质体转染[5,6].虽然这些方法广泛使用,但是存在很大的局限性,如转入效率低,细胞毒性大等.因此,寻找一种高效、无毒和能够穿过细胞的物质势在必行.     

肝靶向穿膜肽与家蝇天蚕素基因的融合及其分子特征分析

本研究利用改进SOE-PCR技术构建肝靶向穿膜肽(HTPP)与家蝇天蚕素(MDC)融合基因并对其分子特征进行了预测和分析。结果表明:成功融合了HTPP与MDC,并构建了HTPP-MDC融合基因的克隆重组质粒HTPP-MDC/pMD20-T。PCR和KpnⅠ/HindⅢ双酶切结果显示获得与预期大小一致的基因片段,测序结果显示获得的基因序列没有发生突变,与预期完全一致。分子特征分析表明,该融合基因编码60个氨基酸,分子量为6516.2Da,理论等电点为9.31,二级结构主要由α-螺旋、无规则卷曲、延伸链和β-转角组成。研究结果为HTPP-MDC后续的功能研究奠定了基础,同时也为应用SOE-PCR技术构建融合基因提供了有益借鉴。     

膜穿透肽的应用与穿膜机制研究

膜穿透肽(membrane penetrating peptide,MPP)能引导大分子物质穿透细胞膜.应用MPP为载体,引导神经营养分子通透血脑屏障进入神经元,能有效治疗中枢神经系统疾病;在基因治疗方面, MPP引导干扰小RNA进行基因治疗,避免了使用病毒载体等一些传统基因治疗方法的毒副作用.穿膜机制研究证实 MPP通透细胞膜的过程分为三个阶段:与细胞表面结合;细胞巨胞饮摄取 MPP;MPP从胞饮体中逃逸入胞质,其中最后阶段是限速步骤.随着对多肽片段的深入研究和穿膜机制的逐渐明晰,MPP的应用将会更为深入和广泛.     

穿膜肽的内化机制及其应用

穿膜肽是一类具有特殊穿膜功能的多肽分子,能携带其它分子甚至超分子颗粒穿膜进入细胞内部．早期研究认为,其进胞是一种无需受体、也不存在饱和状态的非经典胞吞行为．近年研究表明,其穿膜机制可能与其含有的氨基酸种类有很大关系．现在,穿膜肽的穿膜过程称为巨型胞饮行为,它与传统的胞吞形式很相似．当然,还可能存在着其它的进胞方式而没有被证明或发现．关于穿膜肽的应用也是人们最感兴趣的,在很多领域的研究都在进行并不断取得进展．不论是生物界还是医学界,穿膜肽都被认为将是一类非常有发展潜力的多肽分子．     

穿膜肽-LacI HPM载体的构建及其DNA结合活性测定

目的：借助穿膜肽TAT高效跨膜的特性和LacI前头肽突变体（LacI HPM）高亲和力结合DNA的特性,构建新型基因转导载体。方法：PCR扩增LacI、Lacl基因前头肽序列、前头肽序列突变体、TAT序列的编码基因,构建前头肽序列突变体和TAT的原核表达载体,可溶性表达TAT-LacI HPM融合蛋白并纯化,在缇冲液中氧化获得TAT-LacI HPM二聚体并浓缩,PCR检测二聚体融合蛋白与质粒的体外结合能力。结果：获得了pET-28a（-4-）-LacI HPM及pET-28a（＋）-TAT-LacI HPM表达质粒,表达纯化并获得二聚化融合蛋白,体外结合实验确定TAT-Lac／HPM二聚体融合蛋白与检测质粒DNA具有特异的高亲和力结合活性。结论：构建了穿膜呔TAT-LacI HPM,为进一步研究其作为新型DNA转运载体的可行性奠定了基础。     

GnRH及其转运肽基因真核表达载体的构建及表达

目的 构建GnRH/TRS与绿色荧光蛋白(GFP)的融合基因并表达.方法 利用DNA重组技术,将GnRH/TRS片段克隆至真核表达载体pEGFP-C1转化DH5 α,重组体质粒pEGFP-C1-GnRH/TRS用LipoGen脂质体进行转染至Hela细胞,核酸序列测定和Western印迹分析基因表达,激光共聚焦荧光显微镜观察活细胞内荧光布局.结果 重组子pEGFP-C1-GnRH/TR成功构建.激光共聚焦荧光显微镜观察结果表明,GnRH/TKS-GFP融合基因的瞬间和稳定表达均获得了相同结果.结论 GnRH/TRS-GFP融合蛋白具有GFP的自发荧光特性,且不影响GnRH/TRS分子在细胞内的正确表达.     

细菌肽转运蛋白的研究进展

细菌的肽转运蛋白包括3种,寡肽转运蛋白(Oligopeptide permease,Opp)、二肽转运蛋白(Dipeptide permease,Dpp)和二/三肽转运蛋白(Di-and tripeptide permease,Dtp)。Opp和Dpp属于ABC型超家族(ATP-binding cassette superfamily)转运蛋白,利用ATP水解产生的能量实现底物转运。对Opp和Dpp研究最多的是胞外肽结合蛋白OppA和DppA,它们起着最初识别与结合底物的重要作用。Dtp属于主要协助转运蛋白超家族(Major facilitator superfamily,MFS),与质子进行底物共转运。细菌肽转运蛋白的晶体结构解析结合大量的生化数据分析,使得人们对其转运机制有了深入的了解。本文对这三种肽转运蛋白的研究进展分别进行综述。     

Identification,expression and tissue distribution of a renalase homologue from mouse

FAD (flavin adenine dinucleotide)-dependent monoamine oxidases play very important roles in many biological processes. A novel monoamine oxidase, named renalase, has been identified in human kidney recently and is found to be markedly reduced in patients with end-stage renal disease (ESRD). Here, we reported the identification of a renalase homologue from mouse, termed mMAO-C (mouse monoamine oxidase-C) after the monoamine oxidase-A and -B (MAO-A and -B). This gene locates on the mouse chromosome 19C1 and its coding region spans 7 exons. The deuced amino acid sequences were predicted to contain a typical secretive signal peptide and a conserved amine oxidase domain. Phylogenetic analysis and multiple sequences alignment indicated that mMAO-C-like sequences exist in all examined species and share significant similarities. This gene has been submitted to the NCBI GenBank database (Accession number: DQ788834). With expression vectors generated from the cloned mMAO-C gene, exogenous protein was effectively expressed in both prokaryotic and eukaryotic cells. Recombinant mMAO-C protein was secreted out of human cell lines, indicating the biological function of its signal peptide. Moreover, tissue expression pattern analysis revealed that mMAO-C gene is predominantly expressed in the mouse kidney and testicle, which implies that kidney and testicle are the main sources of renalase secretion. Shortly, this study provides an insight into understanding the physiological and biological functions of mMAO-C and its homologues in endocrine.     

Nitrate transporters and peptide transporters

In higher plants, two types of nitrate transporters, NRT1 and NRT2, have been identified. In Arabidopsis, there are 53 NRT1 genes and 7 NRT2 genes. NRT2 are high-affinity nitrate transporters, while most members of the NRT1 family are low-affinity nitrate transporters. The exception is CHL1 (AtNRT1.1), which is a dual-affinity nitrate transporter, its mode of action being switched by phosphorylation and dephosphorylation of threonine 101. Two of the NRT1 genes, CHL1 and AtNRT1.2, and two of the NRT2 genes, AtNRT2.1 and AtNRT2.2, are known to be involved in nitrate uptake. In addition, AtNRT1.4 is required for petiole nitrate storage. On the other hand, some members of the NRT1 family are dipeptide transporters, called PTRs, which transport a broad spectrum of di/tripeptides. In barley, HvPTR1, expressed in the plasma membrane of scutellar epithelial cells, is involved in mobilizing peptides, produced by hydrolysis of endosperm storage protein, to the developing embryo. In higher plants, there is another family of peptide transporters, called oligopeptide transporters (OPTs), which transport tetra/pentapeptides. In addition, some OPTs transport GSH, GSSH, GSH conjugates, phytochelatins, and metals.     

Molecular Recognition Theory of the complementary (antisense) peptide interactions

Molecular Recognition Theory is based on the finding of Blalock et al. (Biochem. Biophys. Res. Commun. 121 (1984) 203–207; Nature Med. 1 (1995) 876–878; Biochem. J. 234 (1986) 679–683) that peptides specified by the complementary RNAs bind to each other with higher specificity and efficacy. This theory is investigated considering the interaction of the sense peptides coded by means of messenger RNA (read in 5′→3′ direction) and antisense peptides coded in 3′→5′ direction. We analysed the hydropathy of the complementary amino acid pairs and their frequencies in 10 peptide–receptor systems with verified ligand–receptor interaction. An optimization procedure aimed to reduce the number of possible antisense peptides derived from the sense peptide has been proposed. Molecular Recognition Theory was also validated by an “in vivo” experiment. It was shown that 3′→5′ peptide antisense of -MSH abolished its cytoprotective effects on the gastric mucosa in rats. Molecular Recognition Theory could be useful method to simplify experimental procedures, reduce the costs of the peptide synthesis, and improve peptide structure modelling.     

Multiplicity and regulation of genes encoding peptide transporters in Saccharomyces cerevisiae

The model eukaryote Saccharomyces cerevisiae has two distinct peptide transport mechanisms, one for di-/tripeptides (the PTR system) and another for tetra-/pentapeptides (the OPT system). The PTR system consists of three genes, PTR1, PTR2 and PTR3. The transporter (Ptr2p), encoded by the gene PTR2, is a 12 transmembrane domain (TMD) integral membrane protein that translocates di-/tripeptides. Homologues to Ptr2p have been identified in virtually all organisms examined to date and comprise the PTR family of transport proteins. In S. cerevisiae, the expression of PTR2 is highly regulated at the cellular level by complex interactions of many genes, including PTR1, PTR3, CUP9 and SSY1. Oligopeptides, consisting of four to five amino acids, are transported by the 12 - 14 TMD integral membrane protein Opt1p. Unlike Ptr2p, distribution of this protein appears limited to fungi and plants, and there appears to be three paralogues in S. cerevisiae. This transporter has an affinity for enkephalin, an endogenous mammalian pentapeptide, as well as for glutathione. Although it is known that OPT1 is normally expressed only during sporulation, to date little is known about the genes and proteins involved in the regulation of OPT1 expression.     

致肝脓肿高毒力肺炎克雷伯菌的表型及分子特征

目的 探究导致肝脓肿高毒力肺炎克雷伯菌的分子特征。方法 用VITEK-2细菌鉴定仪鉴定2014年1月至2016年1月丽水市中心医院肝脓肿患者脓肿穿刺液中分离的细菌。应用拉丝试验鉴定菌株的高粘性,用多位点序列分型（MLST）和血清型分型（K分型）对菌株进行分子分型,并用S1核酸酶脉冲场凝胶电泳（S1-PFGE）对菌株质粒谱进行分析。结果 57例肝脓肿患者接受肝脏脓肿穿刺引流并做脓液培养。44例患者的脓液培养到不同的致病菌,培养阳性率为77.2%。在培养到的44株病原菌中,其中2株为大肠埃希菌,产酸克雷伯菌、金黄色葡萄球菌各1株,而肺炎克雷伯菌为40株,占肝脓肿致病菌的90.9%。40株肺炎克雷伯菌中,拉丝阳性率为67.5%（27/40）,K1为主要血清分型,占62.5%（25/40）,其次为K2型,占17.5%（7/40)。ST23为主要ST分型,占47.5%（19/40）,其次为ST86和ST65,各占7.5%（3/40）。同时发现一些未报道过的致肝脓肿肺炎克雷伯菌新ST分型,如ST218、ST1941、ST76、ST2159、ST660和ST485。40株致肝脓肿肺炎克雷伯菌中总共检测到12种质粒谱,包括带有一个质粒、多个质粒或不带质粒的谱型。其中带有一个近220 kb的质粒谱为主要谱型,共涉及19株菌,占47.5%,12株菌带有一个质粒,大小为140~250 kb。4株菌带有2个或3个质粒,5株菌不含有质粒。结论 拉丝试验和血清学分型不能鉴定所有的高毒力肺炎克雷伯菌;高毒力肺炎克雷伯菌很多为ST23型,但其进化整体上较为分散;高毒力肺炎克雷伯菌菌株可以不携带质粒。     

Multidrug resistance in parasites: ABC transporters, P-glycoproteins and molecular modelling

Parasitic diseases, caused by protozoa, helminths and arthropods, rank among the most important problems in human and veterinary medicine, and in agriculture, leading to debilitating sicknesses and loss of life. In the absence of vaccines and with the general failure of vector eradication programs, drugs are the main line of defence, but the newest drugs are being tracked by the emergence of resistance in parasites, sharing ominous parallels with multidrug resistance in bacterial pathogens. Any of a number of mechanisms will elicit a drug resistance phenotype in parasites, including: active efflux, reduced uptake, target modification, drug modification, drug sequestration, by-pass shunting, or substrate competition. The role of ABC transporters in parasitic multidrug resistance mechanisms is being subjected to more scrutiny, due in part to the established roles of certain ABC transporters in human diseases, and also to an increasing portfolio of ABC transporters from parasite genome sequencing projects. For example, over 100 ABC transporters have been identified in the Escherichia coli genome, but to date only about 65 in all parasitic genomes. Long established laboratory investigations are now being assisted by molecular biology, bioinformatics, and computational modelling, and it is in these areas that the role of ABC transporters in parasitic multidrug resistance mechanisms may be defined and put in perspective with that of other proteins. We discuss ABC transporters in parasites, and conclude with an example of molecular modelling that identifies a new interaction between the structural domains of a parasite P-glycoprotein.     

Amyloid-beta peptide decreases expression and function of glutamate transporters in nervous system cells

Glutamate is an essential excitatory neurotransmitter that regulates brain functions, and its activity is tightly regulated by glutamate transporters. Excess glutamate in the synaptic cleft and dysfunction of excitatory amino acid transporters have been shown to be involved in development of Alzheimer’s disease, but the precise regulatory mechanism is poorly understood. Using a D-[³H]-aspartic acid uptake assay, we found that Aβ_1-42 oligomers impaired glutamate uptake in astrocytes and neurons. In astrocytes, this process was accompanied by reduced expression of GLT-1 and GLAST as detected by Western blot and immunocytofluorescence. However, mRNA levels of EAATs detected by qPCR in astrocytes and neurons were not altered, which suggests that this process is post-translational. Co-localization analysis using immunocytofluorescence showed that ubiquitylation of GLT-1 significantly increased. Therefore, we hypothesized that Aβ_1-42 oligomers-induced endocytosis of astrocytic GLT-1 may be involved in ubiquitylation. In addition, Aβ_1-42 oligomers enhanced secretion of IL-1β, TNF-α, and IL-6 into culture supernatant, which may be correlated with an inflammatory response and altered EAATs expression or function in Alzheimer’s disease. These findings support the idea that dysregulation of the glutamatergic system may play a significant role in pathogenesis of Alzheimer’s disease. Furthermore, enhancing expression or function of EAATs in astrocytes and neurons might be a new therapeutic approach in treatment of Alzheimer’s disease.